Revenue growth masks profit collapse; regulatory costs permanent

₹1880 Cr revenue, +21.8% YoY confirmed. But NPM collapsed to 1.8%, PAT fell 21.7%.

Pharma PL flat YoY (₹197 Cr vs ₹200 Cr). Non-pharma fell from Q4 due to diaper supply issues.

Regulatory labor costs (60% hike Karnataka, 25%+ Telangana, effective 1-June) are structural, not temporary.

Q1 EBITDA ₹651 Cr annualized = ₹2.6 Cr per quarter needed for ₹400 Cr full-year. At current run-rate insufficient.

2 lakh active clients vs. target 2.5–3 lakh missed. B2B failed. No significant expansion planned; maintenance-only mode.

Board-approved but reversed mid-call citing 'market reaction & investor feedback.' Signals reactive mgmt, not conviction on adjacencies.

Claimed 'continuing to grow' in absolute terms, but pharma mix fell 200 bps YoY (13.8% → 10.7%), non-pharma supply-shocked. Absolute sales flat.

FY26 guidance: gross margins stable. Actual: fell ~500 bps to 3.5% EBITDA. Regulatory wage shock (60% KA, 25%+ TG) called permanent.

Previously flagged for expansion. Now: 2 lakh active (vs. 2.5–3 lakh target), B2B/B2C failed, no significant capex planned.

600+ franchisees but 27 closures (avg 8 months old), expectation mismatch from first-time entrepreneurs. Diluting gross margin ~50 bps.

Thought backward integration would help. But after deliberation & Board re-think, decided to hold and plan fund utilization later. Will not discuss further.

Pushed hard early; employees over-aggressive. Repositioning to serve all customers (brand or PL). Growing in absolute terms. Plan 0.3–0.5% quarterly recovery via ads & better sales skills.

Numbers do not change. We are working on private label, cost actions. Tweaked discounts effective 7-July (20%→19%). Confident coming quarters will make upside.

44–45 lakh users (vs. 39–40 lakh June 2025). Added 10 lakh last quarter (renewals). Raised fee from ₹99 to ₹149 month ago. Should see ₹10–11 Cr top-line impact FY27.

Minimum wages rose 60% KA, 25%+ TG (effective 1-June). Only 1 month impact in Q1. Stopped retention bonus (by design wages rose). Monitoring non-statutory incentives & private label mix for relief.

100 bps margin impact Q4→Q1 due to PL mix (pharma & non-pharma). Steeper fall in non-pharma. Diaper range disrupted; coming back by end-quarter. Confident non-pharma will grow.

600+ franchisees; expectation mismatch from first-timers. Expect Y vs getting X. Honoring exits, helping replacements. Model being tweaked: faster breakeven support, first-year fee waivers.

Do not track SSSG explicitly. In pharma retail, continuous densification causes self-cannibalization. Model relies on overall growth, not SSSG metric.

Mix impact (100 bps) + cost increase (employee cost rise). Private label pharma -200 bps mix decline Y-o-Y.

Evaluating options. Will present to Board and guide next quarter.

Q1 delivered 146 net (89% CAGR needed for 800). Mix: 131 franchisees, 15 COCO. Management reiterates commitment to core business capex.

Regulatory wage hikes (60% KA, 25%+ TG) permanent. Private label mix recovery (0.3–0.5% quarterly) unproven. Discount tweaks (20%→19%) may offset.

Q1 pharma PL flat YoY, non-pharma supply-shocked. Recovery depends on new marketing (influencers), better sales training, customer acquisition.

Food park & wellness facility approved by Board but reversed mid-call due to 'market feedback.' Reactive decision-making raises execution risk.

Minimum wages rose 60% in Karnataka, 25%+ in Telangana, effective 1-June. Only 1 month impact in Q1; full quarters ahead. CFO called it 'permanent.' Affects all pharmacy staff, reduces already-thin EBITDA margins.

Private label pharma flat Y-o-Y (₹197 Cr vs ₹200 Cr). Non-pharma fell from Q4 due to supply disruptions. Gross margin fell 100 bps due to PL mix decline. Management claims 'absolute growth' but data contradicts. Risk: aggressive re-positioning may annoy customers again.

27 franchisee closures in Q1 (avg 8 months old vs. older closures prior quarter) signal expectation mismatch. First-time entrepreneurs expect Y, get X. Model margin ~50 bps lower than COCO. 600+ operational; attrition risk high.

Revenue +21.8% YoY but PAT -21.7%, EBITDA margin halved (3.5% vs. ~8%). Suggests costs rising faster than revenue. Store-level ROCE strong (63%), but company-level margin collapsed due to warehouse inventory (30–32 days sales), corporate overhead, logistics.

₹40 Cr capex for food park & wellness facility approved by Board but held mid-call citing 'wisdom of the masses' & investor feedback. Signals reactive management, not strategic vision. Raises questions on capital allocation discipline.